Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | LRP6 | O75581 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | EDNRB | P24530 | 1/20 | 0.30 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200975 | 0.80 | CNR2 (0.33) | SLC10A2APPMAOBMAOACALM1 | |
| SCHEMBL16385373 | 0.79 | MAOB (0.33) | SLC10A2APPMAOBMAOACALM1 | |
| SCHEMBL6200639 | 0.74 | RET (0.33) | KMT2AMAPT | |
| SCHEMBL7846237 | 0.74 | APP (0.34) | APPMAOBMAOACALM1MEN1 | |
| SCHEMBL7837755 | 0.74 | CNR2 (0.35) | SLC10A2APPMAOBMAOACALM1 | |
| SCHEMBL7846110 | 0.68 | CNR2 (0.37) | SLC10A2APPCALM1MEN1KMT2A | |
| SCHEMBL6201251 | 0.68 | LMNA (0.35) | MAPTCNR2ALDH1A1 | |
| SCHEMBL7837233 | 0.67 | MEN1 (0.35) | SLC10A2APPMAOBMAOACALM1 | |
| SCHEMBL6200633 | 0.66 | MMP2 (0.38) | MAOBMEN1KMT2AMAPTCNR2 | |
| SCHEMBL347277 | 0.66 | DDR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425279-A4 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | SEARLE LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050090543-A1 | Method for the preparation of tetrahydrobenzothiepines | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | US | disclosed |
| US-6794544-B2 | APICAL SODIUM CO- DEPENDENT BILE ACID TRANSPORTER (ASBT) INHIBITORS | PHARMACIA CORPORATION | 2004-09-21 | — | — | US | disclosed |
| EP-1425279-A2 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | G.D. Searle LLC (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20040082647-A1 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE, LLC | 2004-04-29 | — | — | US | disclosed |
| US-20030236406-A1 | Method for the preparation of tetrahydrobenzothiepines | BABIAK KEVIN A (US) | 2003-12-25 | — | — | US | disclosed |
| WO-2003022804-A9 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | SEARLE LLC (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030199515-A1 | Method for the preparation of crystalline tetrahydrobenzothiepines | G.D. SEARLE, LLC (US) | 2003-10-23 | — | — | US | disclosed |
| US-6586434-B2 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE, LLC | 2003-07-01 | — | — | US | disclosed |
| WO-2003022804-A2 | METHOD FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES | G.D. SEARLE LLC (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1286984-A2 | METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES | Pharmacia Corporation (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020032329-A1 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE LLC | 2002-03-14 | — | — | US | disclosed |
| WO-2001068637-A2 | METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199515-A1 | Method for the preparation of crystalline tetrahydrobenzothiepines | TPMT, MPST, SULT1A1 | SLC10A2 373/4885APP 1108/4885MAOB 1081/4885 |
| US-20020032329-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | SLC10A2 4044/4885APP 1615/4885MAOB 516/4885 |
| US-20050090543-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | SLC10A2 4044/4885APP 1615/4885MAOB 516/4885 |
| US-20030236406-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | SLC10A2 4031/4885APP 1620/4885MAOB 516/4885 |
| US-20040082647-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | SLC10A2 4044/4885APP 1615/4885MAOB 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.